Raymond Wong, MBChB, MD, MRCP, FHKCP, FHKAM, graduated with a medical degree from the Chinese University of Hong Kong, Hong Kong and received his training in hematology, internal medicine and clinical pharmacology and therapeutics at the Prince of Wales Hospital, Sha Tin, Hong Kong. Dr Wong went on to obtain his medical degree from the Chinese University of Sha Tin, Sha Tin, Hong Kong. He has since gone on to author over 70 articles in peer-reviewed journals, which include Blood, Circulation, JAMA, and the New England Journal of Medicine.
Dr Wong also previously served at the Prince of Wales Hospital Poison Treatment Centre, a tertiary referral centre for patients with poisoning, since its establishment in 2005.
Speaking on transfusions and anticoagulant therapy for hematological malignancies
Dr Wong’s major research interests are hematology and therapeutics. His works include the therapeutic treatment of paroxysmal nocturnal hemoglobinuria (PNH) through C3 inhibition with APL-2, which was found to normalize markers of intravascular and extravascular hemolysis, and also evaluating hematological findings of patients with severe acute respiratory syndrome (SARS). He has also carried out extensive research into Castleman’s disease, whereby he has cared for patients for over 10 years and was involved in the Janssen siltuximab study.